Zeke Capital Advisors LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 11.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,004 shares of the life sciences company’s stock after selling 257 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Illumina were worth $738,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the business. Jennison Associates LLC lifted its stake in Illumina by 3.7% during the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock valued at $1,764,619,000 after acquiring an additional 200,114 shares during the period. Geode Capital Management LLC boosted its position in shares of Illumina by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after acquiring an additional 170,046 shares during the last quarter. Northern Trust Corp lifted its position in Illumina by 0.9% in the first quarter. Northern Trust Corp now owns 1,660,761 shares of the life sciences company’s stock valued at $515,981,000 after buying an additional 14,669 shares during the last quarter. Thoroughbred Financial Services LLC lifted its position in shares of Illumina by 38,516.8% during the second quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after purchasing an additional 873,560 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Illumina by 107.1% during the first quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after purchasing an additional 421,953 shares in the last quarter. Hedge funds and other institutional investors own 90.75% of the company’s stock.
In other news, SVP Charles Dadswell sold 124 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $300.00, for a total transaction of $37,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Omead Ostadan sold 1,260 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $315.32, for a total value of $397,303.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,291 shares of company stock worth $20,840,427. 0.38% of the stock is currently owned by corporate insiders.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The business had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The company’s revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.43 earnings per share. On average, research analysts expect that Illumina, Inc. will post 6.04 EPS for the current year.
Several equities analysts have commented on ILMN shares. Bank of America lowered shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price target on the stock. in a research note on Friday, July 12th. BidaskClub lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 13th. Piper Jaffray Companies dropped their price target on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 30th. Deutsche Bank dropped their price target on shares of Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Finally, Cowen dropped their price target on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company. Illumina presently has an average rating of “Buy” and an average target price of $330.92.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.